-+ 0.00%
-+ 0.00%
-+ 0.00%

Pihlajalinna (HLSE:PIHLIS) Stock Faces Thin Margins After Q3 Results

Simply Wall St·10/28/2026 23:32:35
Listen to the news

Pihlajalinna Oyj just reported Q3 2026 and the headline is simple. Profit is thin for a healthcare provider carrying debt, and that margin squeeze is where the real story sits. Yet traders have treated the stock as if the whole story is already told.

The shares closed at €8.56 on 28 October after a year where the price has slipped steadily, even as Q3 basic earnings per share printed at €0.19 on €122.3 million of revenue and trailing net profit still sits in the tens of millions. Emotion is leaning on the multiple, while the income statement tells a more nuanced tale.

Like the steady revenue base at Pihlajalinna Oyj but wary of thin profitability and leverage risk in a healthcare provider carrying debt? Check out our list of solid balance sheet and fundamentals stocks (207 results) as a reference point for businesses that pair earnings power with sturdier balance sheets.

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): €122.3 million vs. €152.4 million (change of approximately 19.8%)
  • Net Income, excl. extra items (Q3 2026 vs. Q3 2025): €4.3 million vs. €12.1 million (change of approximately 64.5%)
  • Basic EPS (Q3 2026 vs. Q3 2025): €0.19 vs. €0.538117 (change of approximately 64.7%)
  • Trailing 12 month net income, excl. extra items (Q3 2026 TTM vs. Q3 2025 TTM): €18.567 million vs. €38.939 million (change of approximately 52.3%)

Tired of chewing through dense earnings releases and spreadsheet tabs for Pihlajalinna Oyj? Get the full story in a clean visual format that pulls together the company’s recent profitability trend and broader financial picture in the company report for Pihlajalinna Oyj.

HLSE:PIHLIS Trailing 12-Month Earnings & Revenue History as at Oct 2026
HLSE:PIHLIS Trailing 12-Month Earnings & Revenue History as at Oct 2026

Pihlajalinna’s Defensive Appeal Under Real Earnings Pressure

Pihlajalinna is often framed as a defensive healthcare platform with recurring style contracts, yet the latest figures soften that argument. Q3 revenue of €122.3 million and net income of €4.3 million both sit well below the prior year’s levels, and trailing net profit of €18.567 million is roughly half the previous period. The lowered 2026 earnings guidance after outsourcing expiries and residential divestments also points to a less cushioned earnings base, so the defensive label now leans more on sector than on recent financial momentum.

Guidance Cut Highlights Execution And Contract Risk

The more cautious storyline around Pihlajalinna finds firmer support in the new numbers. Earnings guidance for 2026 has been reduced after outsourcing agreements expired and residential care units were sold, which underlines dependence on large public contracts and portfolio reshaping. Q3 profit of €4.3 million compares with €12.1 million a year earlier and trailing net income of €18.567 million is well down from €38.939 million. The recent 30 day share price decline of 21.5% suggests investors are already responding to these pressure points in the business model.

After a guidance cut tied to expiring outsourcing contracts, residential divestments and a 21.5% 30 day share price fall, it is fair to ask if Pihlajalinna Oyj’s thinner earnings base and debt load are just early warning signs. Review our independent risk analysis for Pihlajalinna Oyj which shows 2 important warning signs

Hunt For Mispriced Earnings Power

Pihlajalinna Oyj highlights how sentiment can shift when guidance tightens and contract risk becomes more visible. The real opportunity is locating stocks that could be undervalued before the market fully reprices their earnings power.

  • Company 1 - 44% below our estimate - supplies high voltage cables enabling power connections for data centers and offshore energy projects.
  • Company 2 - 31% below our estimate - turns complex capital markets and restructuring mandates into fee-focused advisory work for large corporate clients.
  • Company 3 - 16% below our estimate - scales biosimilars and complex injectables after investing in biologics facilities and backward-integrated active ingredient production.

Three companies from the same screener. Open every one of the 195 undervalued companies on it →